Abstract: A system to test barrier pressure includes a Christmas Tree (XT) coupled to a wellbore including a downhole pressure barrier. The XT includes a first valve along a flow path and a second valve coupled to the flow path. The system further includes a testing unit that includes a vessel fluidly coupled to the flow path. The testing unit also includes a fluid mover associated with the vessel to draw fluid into or to drive fluid out of the vessel. The testing unit further includes an actuator coupled to the fluid mover to control operation of the fluid mover. The testing unit is configured to draw a volume of fluid out of the XT and to further return the volume of fluid to the XT.

Abstract: A system and method for carbon capture and storage in a depleted hydrocarbon reservoir or dedicated aquifer is disclosed. A wellhead block includes or supports therewith a barrier subsystem having one or more of at least one isolation gate valve or one or more plugs. The barrier subsystem is to allow access to a well that is associated with the depleted hydrocarbon reservoir or dedicated aquifer. The system includes modulation valves to modulate an injection of a wellhead fluid that includes a carbon component into the wellhead block.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A process for recovery of lithium ions from a lithium-bearing brine includes contacting the lithium-bearing brine with a lithium ion sieve (where that LIS includes an oxide of titanium or niobium) in a first stirred reactor to form a lithium ion complex with the lithium ion sieve, and decomplexing the lithium ion from the lithium ion sieve in a second stirred reactor to form the lithium ion sieve and an acidic lithium salt eluate.

Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract: A series of imidazo[1,2-?]pyrazine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorder; and oncological disorders.

Abstract: Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, wherein: n is 1, 2 or 3 and each R is independently selected from fluoro, chloro, cyano, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy and difluoromethoxy; together with processes for their preparation, pharmaceutical compositions containing them and their use as medicaments.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Abstract: The invention relates to quinazoline derivatives of formula (1) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents —O—, —CH2—, —S—, —SO—, —SO2—, —NR7CO—, —CONR8—, —SO2NR9—, —NR10SO2— or —NR11— (wherein R7, R8, R9, R10 and R11 each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl); R4 represents an optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted group sele